THE PRIORITIZE STUDY: A Pragmatic, Randomized Study of Oral Regimens for Hepatitis C: Transforming Decision-Making for Patients, Providers, and Stakeholders
Latest Information Update: 24 Aug 2022
At a glance
- Drugs Dasabuvir (Primary) ; Elbasvir/grazoprevir (Primary) ; Ledipasvir/sofosbuvir (Primary) ; Ombitasvir/paritaprevir/ritonavir (Primary) ; Ribavirin
- Indications Hepatitis C
- Focus Adverse reactions; Therapeutic Use
- Acronyms PRIORITIZE
- 22 Aug 2022 Results (n=793) assessing improvements in symptoms and functional well-being following viral cure, published in the Journal of Viral Hepatitis
- 13 Jul 2021 Results published in the Hepatology
- 01 Dec 2020 Status changed from active, no longer recruiting to completed.